Takeda Pharmaceutical Co Ltd (TKPHF) stock

TKPHFOTCPharmaceutical PreparationsAlso trades as TAK

Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jun 17, 2026Score 5/30

$39.00+0.36 (+0.93%)

Close on Oct 19, 2026Market cap $134.41BP/E –Yield –

Takeda Pharmaceutical price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Takeda Pharmaceutical's price to sales ratio was 2.2× on Oct 19, 2026, against 1.4× a year earlier. Over the last 5 years it ranged from 1.4× to 2.2×, with a median of 1.7×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Oct 19, 2026	2.2×	+0.5
2025	Dec 31, 2025	1.7×	+0.2
2024	Dec 31, 2024	1.5×	−0.0
2023	Dec 29, 2023	1.6×	−0.2
2022	Dec 30, 2022	1.8×	+0.3
2021	Dec 31, 2021	1.5×	−0.3
2020	Dec 31, 2020	1.8×	−1.4
2019	Dec 31, 2019	3.2×	+1.5
2018	Dec 31, 2018	1.7×	−1.3
2017	Dec 29, 2017	2.9×	–

Where these numbers come from

Parsed from the XBRL in Takeda Pharmaceutical's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is TKPHF.

Compare: TKPHF vs NVO · TKPHF vs RDY · TKPHF vs AZN · TKPHF vs PFE · TKPHF vs LLY

Revenue growth-1.7% · median 16.2%

Gross margin65.1% · median 78.4%

Net margin-3.4% · median 19.3%

Company	Revenue	Growth
TKPHF	¥4.51T	-1.7%
LLY	$86.46B	+45.5%
PFE	$63.70B	-0.2%
AZN	$29.01B	+16.2%
NVO	–	–
RDY	–	–

Company

Exchange: OTC
Industry: Pharmaceutical Preparations
Employees: 47,000
Auditor: KPMG AZSA LLC
SEC CIK: 1395064

Advertisement
300 × 250

Takeda Pharmaceutical price to sales ratio

Price to Sales Ratio at the end of each year

More Takeda Pharmaceutical figures